Corporate Finance
Bergs Securities acted as Sole Manager to Observit in its SEK 26 million directed share issue to Eiffel Investment Group
Bergs Securities acted as sole global coordinator and sole bookrunner in the fully guaranteed SEK 46m rights issue and the SEK 42m private placement of convertible bonds in Abliva
Corporate Finance
Bergs Securities acted as sole global coordinator and sole bookrunner in the fully guaranteed SEK 46m rights issue and the SEK 42m private placement of convertible bonds in Abliva
Abliva develops medicines for the treatment of mitochondrial disease. This congenital, rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.
Related News
Corporate Finance
Bergs Securities acted as sole manager and bookrunner to Initiator Pharma Therapeutics in its SEK 56 million rights issue
Corporate Finance
Bergs Securities assisted Smart Eye in the exercise of an incentive program resulting in 497 280 newly issued shares of which around half was divested through a block trade